Monteplase
Alternative Names: Cleactor; E 6010Latest Information Update: 05 Nov 2023
At a glance
- Originator ZymoGenetics
 - Developer Eisai; Eisai Co Ltd
 - Class Plasminogen activator enzymes; Thrombolytics
 - Mechanism of Action Plasminogen activators
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 
Highest Development Phases
- Marketed Embolism; Myocardial infarction; Thrombosis
 - Discontinued Stroke
 
Most Recent Events
- 12 Oct 2010 ZymoGenetics has been acquired by Bristol-Myers Squibb
 - 02 Aug 2005 Launched for Embolism in Japan (Injection)
 - 29 Jul 2005 Discontinued - Phase-II for Stroke in Japan (Injection)